Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s program dropped from Novartis’ pipeline, a Swiss biotech’s Nasdaq ambitions, a hepatitis B approval and new directions in RNA medicines and neuroscience.
Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers cancer vaccine follow-up, changes to kidney and obesity trials, and two developments in AI-enabled drug discovery. Here are six updates worth catching up on.
Beyond the main headlines, European biotech kept moving this week. Lundbeck and Neurosterix advanced neurological drug programs, Rewind secured funding for myelin repair, and Beactica selected a cancer degrader. Plus, new findings from iOnctura and Coave. Here’s your weekly catch-up.